首页> 外文期刊>International journal of oncology >Hyperthermia enhances cytotoxicity of amine oxidase and spermine on drug-resistant LoVo colon adenocarcinoma cells
【24h】

Hyperthermia enhances cytotoxicity of amine oxidase and spermine on drug-resistant LoVo colon adenocarcinoma cells

机译:热疗可增强胺氧化酶和精胺对耐药性LoVo结肠腺癌细胞的细胞毒性

获取原文
获取外文期刊封面目录资料

摘要

Hyperthermia is currently receiving widespread attention when associated with other therapeutic modalities, such as irradiation or chemotherapy, in the treatment of cancer. The occurrence of resistance to cytotoxic pharmacological agents in tumor cells, associated with several phenotypic alterations, is one of the major obstacles to successful anticancer chemotherapy. We investigated a new strategy to overcome multidrug resistance (MDR) cancer cells, using bovine serum amine oxidase (BSAO), which forms toxic products from spermine (H2O2 and aldehydes). The cytotoxicity of the products was evaluated in drug-sensitive (LoVo WT) and multidrug-resistant (LoVo DX) colon adenocarcinoma cells at 37 and 42°C, using a clonogenic cell survival assay. Cytotoxicity was considerably enhanced at 42°C. Both toxic species contributed to the thermal enhancement of cytotoxicity induced by BSAO and spermine. Cytotoxicity was eliminated in the presence of catalase and aldehyde dehydrogenase (ALDH). An interesting finding was that BSAO and spermine at <1 μM, which were non toxic at 37°C, became cytotoxic at 42°C and resemble thermosensitizers. Cell survival results and electron microscopy investigations suggest that, at 42°C, LoVo DX cells are not resistant to the cytotoxic enzymatic oxidation products of spermine, as was already demonstrated in these cells at 37°C. Moreover, microscopy modifications caused by both toxic products were more pronounced in LoVo DX than in LoVo WT cells, where morphological cytoplasmatic alterations were shown. Our findings suggest that hyperthermia combined with the enzymatic toxic oxidation products of spermine might be a promising anticancer strategy, mainly against MDR tumor cells.
机译:当与其他放射治疗或化学疗法相结合时,热疗目前在癌症中受到广泛关注。与几种表型改变有关的肿瘤细胞中对细胞毒性药理学药物的抗药性是成功进行抗癌化学治疗的主要障碍之一。我们研究了一种使用牛血清胺氧化酶(BSAO)克服多药耐药性(MDR)癌细胞的新策略,该酶从精胺中形成有毒产物(H2O2和醛类)。使用克隆形成细胞存活测定法在37和42°C的药物敏感性(LoVo WT)和多药耐药性(LoVo DX)结肠腺癌细胞中评估了产品的细胞毒性。在42℃下细胞毒性显着增强。两种有毒物质均有助于由BSAO和精胺诱导的细胞毒性的热增强。在过氧化氢酶和醛脱氢酶(ALDH)的存在下消除了细胞毒性。有趣的发现是<1μM的BSAO和精胺在37°C时无毒,在42°C时具有细胞毒性,类似于热敏剂。细胞存活结果和电子显微镜研究表明,在42°C时,LoVo DX细胞对精胺的细胞毒性酶氧化产物不具有抗性,正如这些细胞在37°C时已证明的那样。此外,由LoVo DX引起的这两种有毒产物引起的显微镜改变比在LoVo WT细胞中表现出胞浆形态学改变的更为明显。我们的发现表明,热疗与精胺的酶促毒性氧化产物结合可能是一种有前途的抗癌策略,主要针对MDR肿瘤细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号